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background: Paclitaxel has been successfully used as a drug of choice in drug-coated balloons and its antirestenotic effect is well documented 
preclinically and clinically. Although paclitaxel was reported to be detected in the arterial wall at 6 months post PCB, it is still not quite clear how a 
single intraarterial drug application inherent to paclitaxel-coated balloons (PCB) is capable of such sustained effect. This study investigated the very 
long-term (beyond 6 months) levels of paclitaxel in arterial segments following a PCB delivery.
Methods: The Cotavance PCB catheters (coated with 3μg/mm2 paclitaxel) were deployed in the superficial femoral and external iliac arteries of 
3 domestic Yorkshire (30 day only) and 12 Yucatan miniswine: 3 animals each at 30 days, 7.5 months, 9 months and 18 months, respectively. At 
termination, arterial segments were collected for analysis of paclitaxel concentration in the treated vessels.
results: Mean arterial paclitaxel concentrations at 30 days were 5385±5428 ng/g of tissue in the Yucatan miniswine, about 6 times lower than in 
the domestic Yorkshire swine in this study, and in literature. The reason for this inter-strain difference is not immediately apparent. Paclitaxel was still 
detectable above the lowest limit of quantification (LLQ, defined by the analytical laboratory as 0.3 ng/mg) in the treated arterial segments at very 
long-term follow-up: 49±50 ng/g at 7.5 months, 21±30 ng/g at 12 months and 12±7 ng/g at 18 months.
conclusions: Paclitaxel remains detectable above the LLQ by contemporary analytical methods up to 18 months after single application from 
a clinically used DCB. The retention of paclitaxel in the tissue for the first 6 months post single application is likely responsible for the sustained 
antirestenotic effect of DCB. On the other hand, the biological impact of the minimal paclitaxel concentrations still detected between 6 and 18 
months is likely negligible. Future preclinical studies of DCB will likely have to assume a higher level of clinically relevant cutoff value of arterial 
paclitaxel concentration to avoid infinite follow-up length.
